奥希替尼成功治疗携带 - 突变的同步性小细胞肺癌和肺腺癌 - Suppr

Suppr

超能文献

Successful Treatment of -Mutant Synchronous SCLC and Lung Adenocarcinoma With Osimertinib.

作者信息

Batra Ullas, Nathany Shrinidhi, Sharma Mansi, Mehta Anurag, Jain Parveen, Bansal Abhishek

机构信息

Department of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Center, New Delhi, India.

Molecular Diagnostics, Rajiv Gandhi Cancer Institute and Research Center, New Delhi, India.

出版信息

JTO Clin Res Rep. 2020 Sep 12;2(1):100098. doi: 10.1016/j.jtocrr.2020.100098. eCollection 2021 Jan.

DOI:10.1016/j.jtocrr.2020.100098

PMID:34589969

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8474249/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aab0/8474249/8c6ee1808281/gr1.jpg

相似文献

Successful Treatment of -Mutant Synchronous SCLC and Lung Adenocarcinoma With Osimertinib.奥希替尼成功治疗携带 - 突变的同步性小细胞肺癌和肺腺癌

JTO Clin Res Rep. 2020 Sep 12;2(1):100098. doi: 10.1016/j.jtocrr.2020.100098. eCollection 2021 Jan.

A case of osimertinib-resistant lung adenocarcinoma responded effectively to alternating therapy.一例奥希替尼耐药的肺腺癌对交替疗法有效反应。

Ann Transl Med. 2018 Dec;6(23):464. doi: 10.21037/atm.2018.11.25.

Small-Cell Carcinoma Transformation of Pulmonary Adenocarcinoma after Osimertinib Treatment: A Case Report.奥希替尼治疗后肺腺癌转化为小细胞癌：一例报告

Case Rep Oncol. 2018 May 29;11(2):323-329. doi: 10.1159/000489603. eCollection 2018 May-Aug.

Dynamic changes of acquired T790M mutation and small cell lung cancer transformation in a patient with EGFR-mutant adenocarcinoma after first- and third-generation EGFR-TKIs: a case report.1例EGFR突变型腺癌患者在第一代和第三代EGFR-TKIs治疗后获得性T790M突变及小细胞肺癌转化的动态变化：病例报告

Transl Lung Cancer Res. 2020 Feb;9(1):139-143. doi: 10.21037/tlcr.2020.01.07.

Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review.奥希替尼诱发间质性肺病后使用阿美替尼成功治疗EGFR T790M突变型非小细胞肺癌：一例报告及文献综述

Ann Transl Med. 2021 Jun;9(11):950. doi: 10.21037/atm-21-2823.

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma.奥希替尼用于治疗表皮生长因子受体第20外显子插入阳性肺腺癌。

EXCLI J. 2019 Oct 7;18:893-898. doi: 10.17179/excli2019-1786. eCollection 2019.

A Rare Case of Small Cell Lung Cancer With an Epidermal Growth Factor Receptor Mutation and Its Response to Osimertinib.1例伴有表皮生长因子受体突变的小细胞肺癌及其对奥希替尼的反应的罕见病例

Cureus. 2021 May 20;13(5):e15136. doi: 10.7759/cureus.15136.

EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer.EGFR阳性非小细胞肺癌转化为小细胞肺癌化疗后出现EGFR T790M突变。

Respir Med Case Rep. 2018 Mar 16;24:19-21. doi: 10.1016/j.rmcr.2018.03.009. eCollection 2018.

Small-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathology.肺腺癌中小细胞癌：分子病理时代的新认识。

J Thorac Oncol. 2013 Oct;8(10):1265-71. doi: 10.1097/JTO.0b013e3182a407fa.

L718Q mutation occurs without T790M mutation in a lung adenocarcinoma patient with acquired resistance to osimertinib.在一名对奥希替尼获得性耐药的肺腺癌患者中，出现了L718Q突变且无T790M突变。

Ann Transl Med. 2019 May;7(9):207. doi: 10.21037/atm.2019.04.37.

引用本文的文献

Heterogeneity and co-occurrence of resistance mechanisms in EGFR-TKI-induced NSCLC to SCLC transformation: a case report.表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）诱导的非小细胞肺癌向小细胞肺癌转化中耐药机制的异质性与共现：一例报告

AME Case Rep. 2025 Jun 18;9:85. doi: 10.21037/acr-24-67. eCollection 2025.

Baseline retinoblastoma transcriptional corepressor 1 (Rb1) functional inactivation is a pre-requisite but not sufficient for small-cell histological transformation in epidermal growth factor receptor (EGFR) mutant lung adenocarcinomas post-tyrosine kinase inhibitor therapy.基线视网膜母细胞瘤转录共抑制因子1（Rb1）功能失活是表皮生长因子受体（EGFR）突变型肺腺癌在酪氨酸激酶抑制剂治疗后发生小细胞组织学转化的一个先决条件，但并不充分。

Virchows Arch. 2025 Feb 21. doi: 10.1007/s00428-025-04054-0.

Histological transformation in lung adenocarcinoma: Insights of mechanisms and therapeutic windows.肺腺癌中的组织学转化：机制与治疗时机的见解

J Transl Int Med. 2024 Nov 6;12(5):452-465. doi: 10.1515/jtim-2024-0019. eCollection 2024 Nov.

Molecular and Genetic Advances in Small Cell Lung Cancer Landscape: From Homogeneity to Diversity.小细胞肺癌全景中的分子和遗传进展：从同质性到多样性。

Int J Mol Sci. 2023 Dec 22;25(1):224. doi: 10.3390/ijms25010224.

Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature Review.外显子 18-EGFR 突变型转化小细胞肺癌：病例报告及文献复习。

Curr Oncol. 2023 Mar 20;30(3):3494-3499. doi: 10.3390/curroncol30030265.

Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review.小细胞肺癌转化作为表皮生长因子受体突变型肺腺癌对奥希替尼耐药的一种机制：病例报告及文献综述

Front Oncol. 2021 Apr 26;11:642190. doi: 10.3389/fonc.2021.642190. eCollection 2021.

本文引用的文献

Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.联合型小细胞肺癌与非小细胞肺癌不同组织学成分的临床病理与基因组学比较。

Lung Cancer. 2018 Nov;125:282-290. doi: 10.1016/j.lungcan.2018.10.006. Epub 2018 Oct 9.

A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics.从非小细胞肺癌到小细胞肺癌的转化：分子和治疗特征简述。

J Thorac Oncol. 2019 Jan;14(1):130-134. doi: 10.1016/j.jtho.2018.08.2028. Epub 2018 Sep 11.

Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.肺腺癌演变为小细胞癌的克隆进化史和遗传预测因子。

J Clin Oncol. 2017 Sep 10;35(26):3065-3074. doi: 10.1200/JCO.2016.71.9096. Epub 2017 May 12.

Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.非小细胞肺癌向小细胞肺癌的转变：分子驱动因素及起源细胞

Lancet Oncol. 2015 Apr;16(4):e165-72. doi: 10.1016/S1470-2045(14)71180-5.

Small-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathology.肺腺癌中小细胞癌：分子病理时代的新认识。

J Thorac Oncol. 2013 Oct;8(10):1265-71. doi: 10.1097/JTO.0b013e3182a407fa.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验